MNPR Company Profile and Key Details

Q: Who are the executives of MNPR?

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MScCo-Founder, Chief Executive Officer, Pres & DirectorMs. Kim R. Tsuchimoto CPAChief Financial Officer, Sec., Treasurer & DirectorMr. Andrew J. Cittadine M.B.A.Chief Operating OfficerDr. Patrice P. Rioux M.D., Ph.D.Acting Chief Medical Officer

NASDAQ : MNPR

Monopar Therapeutics

$70.92

2.29+3.34%

At Close 4:00 PM

64.5

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Monopar Therapeutics Inc. (MNPR) stock declined over -0.59%, trading at $70.50 on NASDAQ, down from the previous close of $70.92. The stock opened at $70.28, fluctuating between $70.15 and $74.33 in the recent session.

Stock Snapshot

70.92

Prev. Close

471.12M

Market Cap

70.15

Day Low

-17.8

P/E Ratio

-3.96

EPS (TTM)

-0.53

Cash Flow per Share

70.28

Open

6.68M

Number of Shares

74.33

Day High

64.1%

Free Float in %

0.37

Book Value

232.97K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 22, 2025	68.55	73.25	68.37	70.92	172.04K
Dec 19, 2025	65.77	70.11	65.77	68.63	518.17K
Dec 17, 2025	71.69	73.00	66.93	67.70	164.13K
Dec 16, 2025	75.21	75.21	69.21	71.47	330.33K
Dec 15, 2025	74.88	77.45	74.18	75.12	145.29K
Dec 12, 2025	76.51	76.90	73.63	74.61	246.27K
Dec 11, 2025	78.72	79.02	75.00	77.05	112.13K
Dec 10, 2025	75.13	79.31	74.85	78.22	164.8K
Dec 09, 2025	76.82	78.95	74.51	75.44	211.66K
Dec 08, 2025	80.40	83.86	75.26	76.43	191.41K
Dec 05, 2025	79.79	85.01	79.50	80.38	103.71K
Dec 04, 2025	75.47	79.90	75.47	79.47	153.35K
Dec 03, 2025	77.48	79.65	74.00	77.18	187.78K
Dec 02, 2025	82.99	84.04	75.69	75.94	378.35K
Dec 01, 2025	84.88	87.97	82.27	83.06	100.67K
Nov 28, 2025	87.66	91.79	84.00	86.18	82.44K
Nov 26, 2025	88.03	88.88	83.86	87.36	83.36K
Nov 25, 2025	93.06	98.00	85.91	88.47	137.86K
Nov 24, 2025	92.94	100.50	90.00	92.75	169.04K
Nov 21, 2025	82.54	94.45	82.54	91.56	96.51K

Contact Details

Wilmette, IL 60091

United States

https://www.monopartx.com 847 388 0349

About Company

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Espa�ol de Investigaci�n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Stock Peers

ARGX

-2.95-0.35%

argenx SE$852.04 REGN

11.4+1.48%

Regeneron Pharmaceuticals, Inc.$779.36 MDGL

11.81+2.00%

Madrigal Pharmaceuticals, Inc.$602.83 UTHR

-3.34-0.65%

United Therapeutics Corporation$513.79 VRTX

4.11+0.90%

Vertex Pharmaceuticals Incorporated$460.31 ALNY

7.5+1.87%

Alnylam Pharmaceuticals, Inc.$407.73 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

7.48+2.74%

Praxis Precision Medicines, Inc.$280.40 KRYS

8.81+3.66%

Krystal Biotech, Inc.$249.61 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Monopar Therapeutics Inc. (NASDAQ:MNPR) closed at $70.50 USD, losing -$0.42 (-0.59%) from the previous close of $70.92. The stock is currently mid-range between its 52-week high and low $21.00 and $105.00. With a market capitalization of about $471.12 million, Monopar Therapeutics Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.47). Key stats such as the average daily volume over the past year has been around 142.80 thousand shares, trading with heavier-than-usual volume. Headquartered in Wilmette, IL, Monopar Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Chandler D. Robinson, the company employs approximately 14 people and listed since December 19, 2019. Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -8.63%, SMA50 -12.59%, SMA200 35.0%). The stock’s 14-day RSI is 41.3 (neutral), while the ATR of 5.87 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.46% below its high and over 237.71% above its low. Average 10-day trading volume of 265.99 thousand shares is significantly above the 3-month average of 139.79 thousand, indicating heightened recent market interest.

Valuation Metrics

Monopar Therapeutics Inc. trades at a P/E ratio of -0.15, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -0.22, also above market averages.

Dividend & Fair Value

Monopar Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.99. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Monopar Therapeutics Inc. generated EPS of -$3.44 over the past year. Five-year average earnings growth is -15.56%. Wall Street analysts project EPS growth of 7.66% annually over the next five years. The latest quarter delivered EPS of -$0.48. The next quarter is forecast at -$0.45. Next year's EPS is expected at $2.02. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $142.00 to $40.00. The high target offers 100.23% upside. The low target suggests -43.6% downside. The mean target is $87.38. This offers 23.21% upside. Monopar Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 4.35%. The prior quarter beat by -25.53%. Over the last six quarters, Apple has recorded several small beats. These include 11.11% in August 09, 2024.

Shareholding & Insider Activity

Monopar Therapeutics Inc. has 6.17 million shares outstanding. The public float is 2.94 million shares, elevated short interest at 7.00% of float. This equals 135.44 thousand shares. The short ratio is 3.59 days. Institutional investors hold 78.76% of the float. Insiders own 34.25%. Hendricks Diane holds 468.75 thousand shares, Tactic Pharma LLC has 272.03 thousand shares and Cittadine Andrew has 186.13 thousand shares. Over the past six months, insider transactions show net selling. They sold 593.19 thousand shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Monopar Therapeutics has not generated any revenue. Returns are negative, with ROA at -114.39% and ROE at -150.37%.
On valuation metrics, Monopar Therapeutics trades at a P/E of -0.15, P/S of 0.00 and P/B of 0.00. The current ratio is 56.10 and quick ratio is 56.10. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -29.62.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Monopar Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $8.83M (margin 0.0%). Net income was- $8.40M (EPS - $0.61).
The company ended the quarter with $7.27M in cash and short-term investments, a total debt of $0.00, and net debt of - $7.27M. Total assets were $7.35M, with equity of $5.59M. Financials further reflected weakness, with operating cash flow of - $7.86M, free cash flow of - $7.86M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Monopar Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.89%, with price expected at $61.78 by January 05, 2026, within a range of $57.51 to $66.26 3-Month Outlook: Projected fall of -41.77%, reaching $41.30 by March 20, 2026, with a range of $39.78 to $42.85. 1-Year Outlook: Projected gain of 32.52%, with price at $93.98 by December 22, 2026, within a range of $88.85 to $100.98.

Key Takeaways

Monopar Therapeutics Inc. (NASDAQ:MNPR) shares are up 222.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Monopar Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.15. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $66.08, suggesting -6.82% downside. Our AI forecast model points to short-term weakness (-12.89% over two weeks), a medium-term fall (-41.77% over three months), and a longer-term gain (32.52% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Monopar Therapeutics Inc. (MNPR) stock price?

Monopar Therapeutics Inc. (NASDAQ: MNPR) stock price is $70.50 in the last trading session. During the trading session, MNPR stock reached the peak price of $74.33 while $70.15 was the lowest point it dropped to. The percentage change in MNPR stock occurred in the recent session was -0.59% while the dollar amount for the price change in MNPR stock was - $0.42.

MNPR's industry and sector of operation?

The NASDAQ listed MNPR is part of Biotechnology industry that operates in the broader Healthcare sector. Monopar Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MNPR?

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Co-Founder, Chief Executive Officer, Pres & Director
Ms. Kim R. Tsuchimoto CPA
Chief Financial Officer, Sec., Treasurer & Director
Mr. Andrew J. Cittadine M.B.A.
Chief Operating Officer
Dr. Patrice P. Rioux M.D., Ph.D.
Acting Chief Medical Officer

How MNPR did perform over past 52-week?

MNPR's closing price is 237.71% higher than its 52-week low of $21.00 where as its distance from 52-week high of $105.00 is -32.46%.

How many employees does MNPR have?

Number of MNPR employees currently stands at 14.

Link for MNPR official website?

Official Website of MNPR is: https://www.monopartx.com

How do I contact MNPR?

MNPR could be contacted at phone 847 388 0349 and can also be accessed through its website. MNPR operates from 1000 Skokie Boulevard, Wilmette, IL 60091, United States.

How many shares of MNPR are traded daily?

MNPR stock volume for the day was 232.97K shares. The average number of MNPR shares traded daily for last 3 months was 142.8K.

What is the market cap of MNPR currently?

The market value of MNPR currently stands at $471.12M with its latest stock price at $70.50 and 6.68M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	14
Beta	1.47
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MNPR Company Profile and Key Details

Monopar Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Company Overview

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways

Valuation Metrics